MORRISVILLE, N.C. — Kevin Gordon, president and chief financial officer of Liquidia Technologies Inc. said he plans to retire from his position on March 1, 2019.

The Morrisville-based biopharmaceutical company said it has started to look for someone to replace Gordon, who has served in the position for only 10 months.

“On behalf of Liquidia’s employees and board of directors, I want to thank Kevin for his many contributions and wish him the best in his next chapter,” said Liquidia CEO Neal Fowler in a statement.

“We have advanced our internal programs and transitioned to a public company over the last year and I am grateful to Kevin for his leadership and significant contributions toward these important milestones.”

Kevin Gordon, president and chief financial officer of Liquidia Technologies Inc., is stepping down.

Liquidia said Gordon is retiring to focus on his work as a member of the board at genome diagnostics company Veracyte Inc. along with other advisory work.

“It has been a privilege to work with Neal and the talented Liquidia team,” said Gordon in a statement. “I am proud of the progress made in our development programs as well as our entry into the public markets. I am committed to assisting with a smooth transition during my remaining time with the company.”

In February, Gordon was hired as CFO and president of Liquidia after having recently served as executive vice president and chief operating officer at the former Quintiles Transnational Holdings Inc. — now IQVIA Inc.

As COO At Quintiles, Gordon was responsible for global operations and contributed to the execution of the merger between IMS Health and Quintiles. He also served as CFO of Quintiles from 2010 to 2015 and oversaw financial strategy and corporate development activities.

Liquidia is a clinical biopharmaceutical company that focuses on improving the performance of medicine by engineering drug particles.

Liquidia is developing two product candidates, LIQ861 for the treatment of PAH and LIQ865 for the treatment of local post-operative pain. Their leading candidate, LIQ861, is currently in phase three clinical trials.

Liquidia’s shares closed Tuesday at $20.91, down 36 cents.

This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism.